Seagen to highlight adcetris® (brentuximab vedotin) clinical progress at the 2022 american society of hematology (ash) annual meeting

Bothell, wash.--( business wire )--seagen inc. (nasdaq: sgen) today announced new data for adcetris® (brentuximab vedotin) will be featured at the upcoming 64th american society of hematology (ash) annual meeting and exposition, taking place december 10-13, 2022. the abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for adcetris in both early- and advanced stage settings of classical hodgkin lymphoma (chl), and in patients with other cd30-expressing lymphomas and other rare cancers.
SGEN Ratings Summary
SGEN Quant Ranking